JPWO2020191270A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020191270A5
JPWO2020191270A5 JP2021556435A JP2021556435A JPWO2020191270A5 JP WO2020191270 A5 JPWO2020191270 A5 JP WO2020191270A5 JP 2021556435 A JP2021556435 A JP 2021556435A JP 2021556435 A JP2021556435 A JP 2021556435A JP WO2020191270 A5 JPWO2020191270 A5 JP WO2020191270A5
Authority
JP
Japan
Prior art keywords
pharmaceutical formulation
stable liquid
liquid pharmaceutical
antibody
uplc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021556435A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526292A5 (https=
JP7695887B2 (ja
JP2022526292A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/023795 external-priority patent/WO2020191270A1/en
Publication of JP2022526292A publication Critical patent/JP2022526292A/ja
Publication of JP2022526292A5 publication Critical patent/JP2022526292A5/ja
Publication of JPWO2020191270A5 publication Critical patent/JPWO2020191270A5/ja
Priority to JP2025094518A priority Critical patent/JP2025131756A/ja
Application granted granted Critical
Publication of JP7695887B2 publication Critical patent/JP7695887B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021556435A 2019-03-21 2020-03-20 抗ｉｌ－３３抗体を含有する安定化製剤 Active JP7695887B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025094518A JP2025131756A (ja) 2019-03-21 2025-06-06 抗ｉｌ－３３抗体を含有する安定化製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962821661P 2019-03-21 2019-03-21
US62/821,661 2019-03-21
PCT/US2020/023795 WO2020191270A1 (en) 2019-03-21 2020-03-20 Stabilized formulations containing anti-il-33 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025094518A Division JP2025131756A (ja) 2019-03-21 2025-06-06 抗ｉｌ－３３抗体を含有する安定化製剤

Publications (4)

Publication Number Publication Date
JP2022526292A JP2022526292A (ja) 2022-05-24
JP2022526292A5 JP2022526292A5 (https=) 2023-03-24
JPWO2020191270A5 true JPWO2020191270A5 (https=) 2023-03-24
JP7695887B2 JP7695887B2 (ja) 2025-06-19

Family

ID=70228884

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021556435A Active JP7695887B2 (ja) 2019-03-21 2020-03-20 抗ｉｌ－３３抗体を含有する安定化製剤
JP2025094518A Pending JP2025131756A (ja) 2019-03-21 2025-06-06 抗ｉｌ－３３抗体を含有する安定化製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025094518A Pending JP2025131756A (ja) 2019-03-21 2025-06-06 抗ｉｌ－３３抗体を含有する安定化製剤

Country Status (19)

Country Link
US (2) US11596690B2 (https=)
EP (1) EP3941522A1 (https=)
JP (2) JP7695887B2 (https=)
KR (1) KR20210141592A (https=)
CN (3) CN119700966A (https=)
AU (1) AU2020241882A1 (https=)
BR (1) BR112021018727A2 (https=)
CA (1) CA3133995A1 (https=)
CL (1) CL2021002440A1 (https=)
CO (1) CO2021011648A2 (https=)
EA (1) EA202192568A1 (https=)
IL (2) IL286024B2 (https=)
MA (1) MA55362A (https=)
MX (1) MX2021011137A (https=)
PH (1) PH12021552092A1 (https=)
SA (1) SA521430229B1 (https=)
SG (1) SG11202109822XA (https=)
TW (2) TW202519263A (https=)
WO (1) WO2020191270A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
KR20230010239A (ko) * 2020-05-11 2023-01-18 메디뮨 리미티드 항-il-33 항체의 제형물
CN113603775B (zh) 2021-09-03 2022-05-20 江苏荃信生物医药股份有限公司 抗人白介素-33单克隆抗体及其应用
CN113842457B (zh) * 2021-11-04 2022-05-20 江苏荃信生物医药股份有限公司 包含抗人白介素-33单克隆抗体的液体制剂
WO2023077685A1 (zh) * 2021-11-04 2023-05-11 江苏荃信生物医药股份有限公司 包含抗人白介素-33单克隆抗体的浓缩溶液的制备方法及液体制剂
WO2026067832A1 (zh) * 2024-09-30 2026-04-02 深圳市小分子新药创新中心有限公司 抗il-33单域抗体及其衍生物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
BRPI0108923B8 (pt) * 2000-03-03 2021-05-25 Cambridge Antibody Tech Limited elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
GB0600351D0 (en) 2006-01-10 2006-02-15 Weston Terence E Safe hypodermic needle
IE20080331A1 (en) 2007-04-26 2009-07-08 Trinity College Dublin Products for altering cytokine activity and methods therefor
AU2008254704A1 (en) 2007-05-18 2008-11-27 Medimmune, Llc IL-33 in inflammatory disease
WO2011031600A1 (en) 2009-09-10 2011-03-17 Schering Corporation Use of il-33 antagonists to treat fibrotic disease
BR112013008366B1 (pt) * 2010-10-06 2022-02-08 Regeneron Pharmaceuticals, Inc Formulações farmacêuticas líquidas estáveis contendo anticorpos anti-receptor de interleucina-4 humana alfa, e recipiente contendo as referidas formulações
EP2768858B1 (en) * 2011-10-18 2018-08-01 Emory University Antibodies directed against influenza
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
PL2892927T3 (pl) * 2012-09-07 2018-11-30 Regeneron Pharmaceuticals, Inc. Sposoby leczenia atopowego zapalenia skóry przez podawanie antagonisty IL-4R
JO3532B1 (ar) * 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
EA201890891A1 (ru) * 2015-10-06 2018-09-28 Ридженерон Фармасьютикалз, Инк. Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
TWI857389B (zh) 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
KR20180106974A (ko) 2017-03-16 2018-10-01 주식회사 엘지화학 항-tnf 알파 항체의 액상 제제
WO2020227515A1 (en) * 2019-05-07 2020-11-12 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
CN112851814B (zh) * 2020-03-17 2023-07-07 西安宇繁生物科技有限责任公司 一种靶向bcma的全人源单链抗体及其制备方法与应用
EP4255451A4 (en) * 2020-12-03 2025-01-01 The Board Of Regents Of The University Of Texas System Methods for identifying lilrb-blocking antibodies
TW202237639A (zh) * 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法

Similar Documents

Publication Publication Date Title
CN106267189B (zh) 含有抗白介素-4受体(il-4r)的抗体的稳定制剂
KR102667484B1 (ko) 안정한 항체 제형
JP6456470B2 (ja) 抗ｐｃｓｋ９抗体を含む安定化製剤
CN103108656B (zh) 含有抗ngf抗体的稳定化制剂
CN102869346B (zh) 含有抗白介素-6受体(il-6r)的抗体的稳定制剂
JP7695887B2 (ja) 抗ｉｌ－３３抗体を含有する安定化製剤
AU2013267301B2 (en) Stabilized formulations containing anti-Dll4 antibodies
JP2023511080A (ja) 安定な抗体製剤
AU2024372916A1 (en) Stable antibody formulation comprising fianlimab
TWI568445B (zh) 含有液態醫藥配製物之預填充針筒
JPWO2020191270A5 (https=)
JPWO2022010988A5 (https=)
RU2024135750A (ru) Составы антитела к рецептору интерлейкина-4 (il-4r)
HK1232793A1 (en) Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
HK1232793B (zh) 含有抗白介素-4 受体(il-4r)的抗体的稳定制剂
EA042167B1 (ru) Стабилизированные композиции, содержащие антитела к рецептору интерлейкина-4 (il-4r)
EA047546B1 (ru) Стабилизированные составы, содержащие антитела анти-pcsk9